These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 27710139)

  • 1. Higher pulse pressure/stroke volume index is associated with impaired outcome in hypertensive patients with left ventricular hypertrophy the LIFE study.
    Mancusi C; Gerdts E; de Simone G; Midtbø H; Lønnebakken MT; Boman K; Wachtell K; Dahlöf B; Devereux RB
    Blood Press; 2017 Jun; 26(3):150-155. PubMed ID: 27710139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of left ventricular mass change during treatment of hypertension.
    Devereux RB; Wachtell K; Gerdts E; Boman K; Nieminen MS; Papademetriou V; Rokkedal J; Harris K; Aurup P; Dahlöf B
    JAMA; 2004 Nov; 292(19):2350-6. PubMed ID: 15547162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events.
    Okin PM; Devereux RB; Jern S; Kjeldsen SE; Julius S; Nieminen MS; Snapinn S; Harris KE; Aurup P; Edelman JM; Wedel H; Lindholm LH; Dahlöf B;
    JAMA; 2004 Nov; 292(19):2343-9. PubMed ID: 15547161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of changes in the electrocardiographic strain pattern during antihypertensive treatment: the Losartan Intervention for End-Point Reduction in Hypertension Study (LIFE).
    Okin PM; Oikarinen L; Viitasalo M; Toivonen L; Kjeldsen SE; Nieminen MS; Edelman JM; Dahlöf B; Devereux RB;
    Circulation; 2009 Apr; 119(14):1883-91. PubMed ID: 19332468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in electrocardiographic left ventricular hypertrophy and risk of major cardiovascular events in isolated systolic hypertension: the LIFE study.
    Larstorp AC; Okin PM; Devereux RB; Olsen MH; Ibsen H; Dahlöf B; Kjeldsen SE; Wachtell K
    J Hum Hypertens; 2011 Mar; 25(3):178-85. PubMed ID: 20505749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Change in pulse pressure/stroke index in response to sustained blood pressure reduction and its impact on left ventricular mass and geometry changes: the life study.
    Palmieri V; Bella JN; Gerdts E; Wachtell K; Papademetriou V; Nieminen MS; Dahlöf B; Devereux RB
    Am J Hypertens; 2008 Jun; 21(6):701-7. PubMed ID: 18437127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exercise and cardiovascular outcomes in hypertensive patients in relation to structure and function of left ventricular hypertrophy: the LIFE study.
    Boman K; Gerdts E; Wachtell K; Dahlöf B; Nieminen MS; Olofsson M; Papademetriou V; Devereux RB
    Eur J Cardiovasc Prev Rehabil; 2009 Apr; 16(2):242-8. PubMed ID: 19369828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pulse pressure, left ventricular function and cardiovascular events during antihypertensive treatment (the LIFE study).
    Gerdts E; Franklin S; Rieck A; Papademetriou V; Wachtell K; Nieminen M; Dahlöf B; Devereux RB
    Blood Press; 2009; 18(4):180-6. PubMed ID: 19562573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Left bundle branch block and cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension study.
    Li Z; Dahlöf B; Okin PM; Kjeldsen SE; Wachtell K; Ibsen H; Nieminen MS; Jern S; Devereux RB
    J Hypertens; 2008 Jun; 26(6):1244-9. PubMed ID: 18475164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophy.
    Fyhrquist F; Dahlöf B; Devereux RB; Kjeldsen SE; Julius S; Beevers G; de Faire U; Ibsen H; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Hille DA; Lyle PA; Edelman JM; Snapinn SM; Wedel H;
    Hypertension; 2005 Apr; 45(4):580-5. PubMed ID: 15790960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reductions in albuminuria and in electrocardiographic left ventricular hypertrophy independently improve prognosis in hypertension: the LIFE study.
    Olsen MH; Wachtell K; Ibsen H; Lindholm LH; Dahlöf B; Devereux RB; Kjeldsen SE; Oikarinen L; Okin PM;
    J Hypertens; 2006 Apr; 24(4):775-81. PubMed ID: 16531808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of pulse pressure with new-onset atrial fibrillation in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint (LIFE) reduction in hypertension study.
    Larstorp AC; Ariansen I; Gjesdal K; Olsen MH; Ibsen H; Devereux RB; Okin PM; Dahlöf B; Kjeldsen SE; Wachtell K
    Hypertension; 2012 Aug; 60(2):347-53. PubMed ID: 22753219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
    Wachtell K; Hornestam B; Lehto M; Slotwiner DJ; Gerdts E; Olsen MH; Aurup P; Dahlöf B; Ibsen H; Julius S; Kjeldsen SE; Lindholm LH; Nieminen MS; Rokkedal J; Devereux RB
    J Am Coll Cardiol; 2005 Mar; 45(5):705-11. PubMed ID: 15734614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: the LIFE study.
    Okin PM; Wachtell K; Kjeldsen SE; Julius S; Lindholm LH; Dahlöf B; Hille DA; Nieminen MS; Edelman JM; Devereux RB
    Circ Arrhythm Electrophysiol; 2008 Dec; 1(5):337-43. PubMed ID: 19808428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In-treatment reduced left atrial diameter during antihypertensive treatment is associated with reduced new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy: The LIFE Study.
    Wachtell K; Gerdts E; Aurigemma GP; Boman K; Dahlöf B; Nieminen MS; Olsen MH; Okin PM; Palmieri V; Rokkedal JE; Devereux RB
    Blood Press; 2010 Jun; 19(3):169-75. PubMed ID: 20438307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In-treatment resolution or absence of electrocardiographic left ventricular hypertrophy is associated with decreased incidence of new-onset diabetes mellitus in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Study.
    Okin PM; Devereux RB; Harris KE; Jern S; Kjeldsen SE; Lindholm LH; Dahlöf B;
    Hypertension; 2007 Nov; 50(5):984-90. PubMed ID: 17893425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study.
    Okin PM; Devereux RB; Gerdts E; Snapinn SM; Harris KE; Jern S; Kjeldsen SE; Julius S; Edelman JM; Lindholm LH; Dahlöf B;
    Circulation; 2006 Mar; 113(12):1588-96. PubMed ID: 16534012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic importance of hemoglobin in hypertensive patients with electrocardiographic left ventricular hypertrophy: the Losartan Intervention For End point reduction in hypertension (LIFE) study.
    Olsen MH; Wachtell K; Beevers G; Dahlöf B; Devereux RB; de Faire U; Fyhrquist F; Ibsen H; Kjeldsen SE; Lederballe-Pedersen O; Lindholm LH; Narayan P; Nieminen MS; Omvik P; Oparil S; Wedel H
    Am Heart J; 2009 Jan; 157(1):177-84. PubMed ID: 19081416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
    Wachtell K; Lehto M; Gerdts E; Olsen MH; Hornestam B; Dahlöf B; Ibsen H; Julius S; Kjeldsen SE; Lindholm LH; Nieminen MS; Devereux RB
    J Am Coll Cardiol; 2005 Mar; 45(5):712-9. PubMed ID: 15734615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of isolated systolic hypertension on normalization of left ventricular structure during antihypertensive treatment (the LIFE study).
    Mancusi C; Gerdts E; De Simone G; Abdelhai YM; Lønnebakken MT; Boman K; Wachtell K; Dahlöf B; Devereux RB
    Blood Press; 2014 Aug; 23(4):206-12. PubMed ID: 24564262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.